STAT

JULY 24, 2024

In 1988, I became one of the first U.S. physicians certified in the new specialty of geriatric medicine, which focuses on the health care of older adults. As an idealistic and optimistic 32-year-old geriatrician, I believed that this branch of medicine would undoubtedly emerge as a vibrant field of medicine, benefiting patients and society. I was also confident that when I reached older adulthood, the health care system would be ready to care for me.

354

354

pharmaphorum

JULY 24, 2024

Stay updated on Matteo Levisetti, the chief medical officer at CUE Biopharma, post ASCO 2024. Learn about his latest research and contributions in the field of biopharma.

115

115

STAT

JULY 24, 2024

Jiankui He, the Chinese scientist who s parked a global uproar in 2018 when he revealed he had created the first gene-edited children , is again out on his own after being dismissed from an academic post. In January 2019, provincial health authorities found that He’s human CRISPR experiments violated national regulations against gene-editing for reproductive purposes.

347

347

Pharma Times

JULY 24, 2024

The neurodegenerative disease is currently the most common cause of dementia

158

158

Speaker: Joe Sharpe and James Carlson

In the world of small business management, the challenge of managing payroll & HR efficiently while scaling operations can be overwhelming. Yet, with the right strategies in place, these challenges can become opportunities for growth and innovation. In this session, Joe Sharpe, Senior Director of Managed Payroll Services at IRIS, will reveal practical methods and expert insights for outsourcing and streamlining payroll processes, resulting in substantial time and resource savings.

STAT

JULY 24, 2024

Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing the biotech closer to joining the highly competitive GLP-1 drug market.  The San Diego-based biotech previously said it was anticipating to start a Phase 2b trial of the therapy, VK2735, after getting positive results from a Phase 2 study.

Drug Development 327

Drug Development 327

The Pharmacist

JULY 24, 2024

The UK’s medicines regulator has approved the use of semaglutide (Wegovy) for cardiovascular prevention in obese and overweight patients with established cardiovascular disease. The Medicines and Healthcare products Regulatory Agency (MHRA) granted the authorisation on Tuesday this week, making it the first weight loss drug to be prescribed as a preventative treatment for cardiovascular events. […] The post MHRA approves new use of semaglutide for cardiovascular prevention appeared first o

106

106

Med Ed 101

JULY 24, 2024

In this post, I will share some questions that I would investigate from this medication list. I have many questions surrounding renal concerns given the use of sevelamer. Sevelamer is a phosphate binder that is typically used to lower phosphate levels for patients with CKD. If this patient truly has CKD and significant impairment, many […] The post Med List Review – Renal Concerns appeared first on Med Ed 101.

102

102

STAT

JULY 24, 2024

For many kids with cerebral palsy, walking is taxing. They might spend thousands of hours step-stepping in physical therapy to make walking easier. In recent years researchers have developed robots to aid this rehabilitation. A new JAMA Network Open study from a team in South Korea found that exoskeletons can improve a child’s gait, balance and motor function.

293

293

Express Pharma

JULY 24, 2024

The burden of diagnosed incident cases of renal cell carcinoma (RCC) is forecast to increase at an annual growth rate (AGR) of 1.40 per cent from around 200,000 cases in 2023 to 230,000 cases in 2033 in the eight major markets (8MM*), according to GlobalData. GlobalData’s latest report, ‘Renal Cell Carcinoma (RCC): Epidemiology Forecast to 2033’, reveals RCC cases are rising because of the longer life expectancy in those with RCC, the increasing prevalence of risk factors, the increasing inciden

100

100

STAT

JULY 24, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Several of my colleagues have joined the newsletter today to bring you the latest biopharma updates. It’s a busy news day, especially for a summer Wednesday, so let’s get straight into it.

Drug Pricing 291

Drug Pricing Drug Development 291

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

pharmaphorum

JULY 24, 2024

The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them of monopolising the supply chain.

Drug Pricing 100

Drug Pricing 100

STAT

JULY 24, 2024

Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for at least 15 months in a large phase 3 trial. The data may be enough to muster approval, but they are unlikely to quell doubts about whether the treatment can provide a cure — as had once been hoped — or a meaningful option for most patients in the U.S. and Europe with the rare blood disorder.

Hospitals 288

Hospitals 288

Express Pharma

JULY 24, 2024

Kiran Mazumdar Shaw, Chairperson, Biocon & Biocon Biologics “The Union Budget for FY25 builds further on the government’s pre-election, Interim Budget and has positive indicators on how the government is looking at India’s economic growth and development. The FM’s emphasis on job creation through skilling is a key underlying theme. Internships at large companies with Government and CSR-backed stipends are the right approach to employability and jobs for the future.

Packaging 97

Packaging 97

STAT

JULY 24, 2024

Sage Therapeutics said Wednesday that an experimental pill failed to quell involuntary muscle shaking in patients with a neurological condition called essential tremor. The negative study result for the drug, called SAGE-324, is a significant setback for Sage’s neurology pipeline, and its effort to develop a successful medicine beyond Zurzuvae, an approved treatment for postpartum depression.

221

221

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

BioPharma Dive

JULY 24, 2024

Autobahn’s lead candidate is designed to stimulate thyroid hormone receptors as a way to complement existing antidepressants.

113

113

STAT

JULY 24, 2024

Cutting-edge FDA-approved therapies made from human cells are now being used to treat cancer, diabetes, and other diseases. Currently, most approved cell-based therapies use an individual’s own cells, but the next generation of these therapies will be made from donor-derived blood and tissue. That raises critical questions about how to recruit, retain, and fairly compensate donors while ensuring their safety throughout the donation process.

Diabetes 216

Diabetes 216

Drug Patent Watch

JULY 24, 2024

In the high-stakes world of pharmaceutical innovation, drafting detailed drug patent claims is a critical process that can make or break a company’s future.

98

98

STAT

JULY 24, 2024

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.

Documentation 186

Documentation 186

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Drug Patent Watch

JULY 24, 2024

As patents expire on blockbuster biologic drugs, manufacturers are increasingly employing a controversial tactic known as “product hopping” to maintain […] Source

98

98

The Pharmacist

JULY 24, 2024

A ‘broader debate’ is needed on the issue of self-selection of Pharmacy (P) medicines within the pharmacist profession, the Pharmacists’ Defence Association (PDA) has insisted. And it has launched a survey of its members to hear their views on the topic. Paul Bennett, RPS chief executive, told The Pharmacist today that the RPS welcomed the […] The post PDA calls for ‘broader debate’ on P med self-selection appeared first on The Pharmacist.

93

93

pharmaphorum

JULY 24, 2024

Explore the latest developments in the life sciences industry with a focus on patient-centred research and development (R&D) at DIA 2024. Chart new horizons and stay updated on key trends shaping the future of healthcare.

90

90

Express Pharma

JULY 24, 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes. This medicine, a GLP-1 receptor agonist, was already approved for use in the treatment of obesity and weight management, as well as in diet, physical activity, and behavioural support.

84

84

pharmaphorum

JULY 24, 2024

MSD's phase 2b/3 data with clesrovimab for RSV prevention in infants sets up a challenge to Sanofi and AstraZeneca's fast-growing Beyfortus

95

95

Drug Patent Watch

JULY 24, 2024

In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility.

105

105

Pharmaceutical Technology

JULY 24, 2024

The crowd and panel gave Gilead a standing ovation after the full data from the Phase III PURPOSE trial was announced at AIDS 2024.

98

98

World Pharma News

JULY 24, 2024

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) rep

80

80

Express Pharma

JULY 24, 2024

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Prolixin Tablets, 1 mg, 2.5 mg, 5mg, and 10 mg, of Apothecon.

79

79

The Pharmacist

JULY 24, 2024

The new pharmacy minister has signalled his commitment to ‘expanding the role’ of pharmacists and ‘better utilising’ their skills. In one of his first written statements to parliament, care minister Stephen Kinnock – who holds the responsibility for pharmacy and general practice – also confirmed the government and NHS England are continuing to consult with […] The post Government committed to ‘expanding role’ of pharmacists appeared first on The Pharmacist.

Community Pharmacies 83

Community Pharmacies 83

pharmaphorum

JULY 24, 2024

Asarina Pharma has abandoned its partner search for Tourette's drug sepranolone and will go into liquidation.

95

95

Pharmaceutical Business Review

JULY 24, 2024

The designation comes after the FDA reviewed the available initial clinical data showing AIC100’s potential to treat recurrent ATC. RMAT designation is aimed at expediting the development and review of regenerative medicine therapies that show potential to fill unmet medical needs. To qualify for RMAT designation, a regenerative medicine therapy must be intended to treat, modify, reverse, or cure a serious condition, and there must be preliminary clinical evidence indicating that the therapy cou

Drug Development 69

Drug Development 69

PharmaTech

JULY 24, 2024

In the second episode of the Ask the Expert video series, Susan J. Schneipp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice-president, Technical, at Parexel, discuss the quality requirements needed when incorporating AI in bio/pharmaceutical development and manufacturing.

69

69

pharmaphorum

JULY 24, 2024

Biogen's $3bn alliance with Sage has had another setback after a drug for essential tremor failed a phase 2 study.

85

85

Pharmafile

JULY 24, 2024

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the approval of Spracato (esketamine) CIII nasal spray as a monotherapy for the treatment of adult patients living with treatment-resistant depression (TRD). The post J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression appeared first on Pharmafile.

64

64